Mandate

Vinge Advises VocaLink

May 16, 2008

BGC – Bankgirocentralen has entered into an agreement with Brittish VocaLink concerning a takeover of operations and development of the bank giro services. Vinge acted as advisors to Vocalink. Vocalink – specialised provider of transaction services for banks – will gradually take over, through a specialized out sourcing agreement, operations and development of the BGC’s services. The agreement was entered into yesterday. Efforts to shift the service will commence during May 2008 and shall be implemented by the start of 2010. Payment transactions will thereafter occur through VocaLink. However BGC’s role and responsibility towards Swedish banks, companies and authorities will remain the same. BGC, wholly owned by Swedish commercial banks, play a central role in the mediation of payments and data between banks and their customers. On a daily basis BGC mediates transactions for SEK 25 to 50 billion.   

Vinge’s team included partner Björn Gustavsson, joined by Lisa Barnekow, Fredrik Dahl, Per Westman and Maria Schultzberg.     

 

Related

Vinge has advised Hansa Biopharma in connection with entering into a financing agreement

Vinge has advised Hansa Biopharma AB (publ), a commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions, listed on Nasdaq Stockholm, in connection with a U.S. convertible note purchase agreement comprising USD 30 million aggregate principal amount of unsecured convertible senior notes.
March 23, 2026

Vinge advises in connection with data center provider EcoDataCenter’s tap issue of SEK 500 million bonds

Vinge has advised in connection with EcoDC Holding AB (publ)'s tap issue of SEK 500 million senior unsecured bonds under the existing framework of up to SEK 2 billion.
March 19, 2026

Vinge has advised Cinclus Pharma in connection with entering into financing agreement

Vinge has advised Cinclus Pharma Holding AB (publ), a late-stage clinical pharmaceutical company developing next-generation treatments for gastric acid-related diseases listed on Nasdaq Stockholm, in connection with a long-term structured credit agreement for a total of up to EUR 28 million divided into four tranches, of which two are convertibles.
March 16, 2026